Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHO6XP)

• Drug Name: MyoDys Drug Info
• Synonyms: PTG11025; TG-5001; Gene therapy (DMD), Transgene; Gene therapy (Duchenne muscular dystrophy), Transgene; Gene therapy (DMD/ BMD), Transgene; Gene therapy (Duchenne muscular dystrophy/ Becker muscular dystrophy), Transgene

Indication

Disease Entry	ICD 11	Status	REF
Duchenne dystrophy	8C70	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMHO6XP

Molecule-Related Drug Atlas

Drug(s) Targeting Dystrophin (DMD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fordadistrogene movaparvovec	DMZ3X7F	Duchenne muscular dystrophy	8C70.1	Phase 3	[3]
WVE-210201	DMHXJ68	Duchenne dystrophy	8C70	Phase 2/3	[4]
SRP-9001	DMR09IH	Duchenne dystrophy	8C70	Phase 2	[5]
Biostrophin	DMS4P6K	Duchenne dystrophy	8C70	Phase 1	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dystrophin (DMD)	TT48MP6	DMD_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009280)
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009280)
• [3] ClinicalTrials.gov (NCT05689164) Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study. U.S.National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of Sarepta Therapeutics.
• [6] Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013 Jun;14(6):373-8.